Stockreport

Sol-Gel Technologies Initiates Pivotal Phase III Clinical Program of TWIN for the Treatment of Acne Vulgaris

Sol-Gel Technologies Ltd.  (SLGL) 
Last sol-gel technologies ltd. earnings: 11/13 07:05 am Check Earnings Report
PDF First subject dosed in pivotal Phase III program evaluating TWIN in subjects with moderate-to-severe acne vulgaris Two Phase III trials expected to enroll a total of ap [Read more]